Lidocaine 4% Urethral Gel
Published March 12, 2014 · Recall initiated: November 1, 2013
Summary
FDA records drug Class II recall D-1098-2014, published March 12, 2014 and initiated November 1, 2013. Recalling firm: Natures Pharmacy & Compounding Center; Status: Terminated; Reported quantity: 104 syringes; Lot: Lot# 101213, Exp. 04/14 Lot# 09202013, Exp. 03/14 Lot# 08272013, Exp. 02/14 Lot# 08022013, Exp. 01/14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.
What to do
Voluntary: Firm initiated · Telephone
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Natures Pharmacy & Compounding Center
- Distributor
- NC
- Lot
- Lot# 101213, Exp. 04/14 Lot# 09202013, Exp. 03/14 Lot# 08272013, Exp. 02/14 Lot# 08022013, Exp. 01/14
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDA5-Fluorouracil pf in methocel 1% opthalMarch 12, 2014
- FDAScopolamine 0.25 opth.March 12, 2014
- FDAPyridoxine (p-f) 100mg/mlMarch 12, 2014
- FDAPapaverine 1nj 30mg/mlMarch 12, 2014
- FDATussin CF Adult Maximum Strength Multi-Symptom Cold liquid (dextromethorphan HBr 10 mg, guaifenesin 200 mg,March 12, 2014
- FDAAcetylcysteine 10% ophthalmicMarch 12, 2014
Questions about this recall
Was Lidocaine 4% Urethral Gel recalled?
Yes. FDA published recall D-1098-2014 on March 12, 2014. Reported hazard: Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.
What should I do if I have this product?
Voluntary: Firm initiated · Telephone